Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756642 | 0.97 | HDAC1 (0.42) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL3385580 | 0.97 | HDAC1 (0.42) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Ethylene SCHEMBL23700090 | 0.95 | HDAC1 (0.40) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Propene SCHEMBL23700062 | 0.88 | HDAC1 (0.36) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL462373 | 0.83 | TP53 (0.46) | TSHRTP53FDPSCA1CA2 | |
| Tetrabuthylammonium SCHEMBL28466197 | 0.82 | SLC22A1 (0.48) | TSHRCYP3A4TP53RECQL | |
| SCHEMBL1270580 | 0.81 | TP53 (0.56) | TP53FDPSCA1CA2 | |
| Acrylamide SCHEMBL6677497 | 0.81 | TSHR (0.42) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL6241631 | 0.79 | TP53 (0.54) | TP53FDPSCA1CA2 | |
| SCHEMBL563944 | 0.79 | TP53 (0.54) | TP53FDPSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115191-A1 | Nilotinib Compositions with Enhanced Solubility | NEOFORM BIOPHARMACEUTICAL LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-12442728-B2 | Preservative solution for heme protein, and method for stabilizing heme protein | EIKEN KAGAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | claimed |
| CN-119977129-A | Butanedisulfonic acid waste liquid neutralization treatment device | 山东鲁抗三叶生物制药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119753047-A | Preparation process of high-purity butanedisulfonic acid ademetionine | 江西诚志生物工程有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119574729-A | Method for detecting antioxidant in adenosylmethionine butanesulfonate for injection | 石家庄四药有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119499265-A | Butanedisulfonic acid adenomethionine for injection and preparation method thereof | 海南倍特药业有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119439655-A | Corrosion-resistant developing solution and preparation method and application thereof | 上海戎洲芯科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119103813-B | Preparation method of high-temperature-resistant butanedisulfonic acid ademetionine for injection | 成都天兴致远生物科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119281120-A | Electrodialysis salifying device for preparing adenosyl methionine butandisulfonate | 江西兄弟医药有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119103813-A | Preparation method of high-temperature-resistant butanedisulfonic acid ademetionine for injection | 成都天兴致远生物科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| EP-1294403-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| EP-1294404-A2 | PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| EP-1294405-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2002100353-A2 | CD10-ACTIVATED PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| WO-2002092112-A1 | ORAL SUPPLEMENT | HOLFORD & ASSOCIATES LIMITED (GB) | 2002-11-21 | — | — | WO | claimed |
| US-20020142955-A1 | Enzyme-cleavable prodrug compounds | E. R. SQUIBB & SONS, L.L.C. | 2002-10-03 | — | — | US | claimed |
| WO-2002000263-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2001095945-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | MEDAREX, INC. (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095943-A2 | PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE | MEDAREX, INC. (US) | 2001-12-20 | — | — | WO | claimed |
| US-5776911-A | Use of (S)-adenosyl-l-methionine (same) and its physiologically tolerated salts for treating reperfusion damage caused by temporary focal ischemia | KNOLL AKTIENGESELLSCAHFT (DE) | 1998-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115191-A1 | Nilotinib Compositions with Enhanced Solubility | TP53, PHF8, SMCHD1 | HDAC1 249/4885HDAC2 358/4885CHRM1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.